CN107536830B - Anti-hepatic fibrosis medicines composition containing diallyl disulfide - Google Patents
Anti-hepatic fibrosis medicines composition containing diallyl disulfide Download PDFInfo
- Publication number
- CN107536830B CN107536830B CN201710872532.8A CN201710872532A CN107536830B CN 107536830 B CN107536830 B CN 107536830B CN 201710872532 A CN201710872532 A CN 201710872532A CN 107536830 B CN107536830 B CN 107536830B
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- myricetin
- diallyl disulfide
- weight
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a kind of anti-hepatic fibrosis medicines composition containing diallyl disulfide, the wherein weight ratio of active constituent diallyl disulfide and myricetin are (1:1)~(1:9).The two kinds of active components of the present invention can generate synergistic function while playing respective effect, significantly treat liver fibrosis.Diallyl disulfide and myricetin source are natural, safe and non-toxic, without side-effects.
Description
Technical field
The present invention relates to pharmaceutical fields, and in particular to a kind of drug for treating liver fibrosis.
Background technology
Liver fibrosis (HF) is that chronic liver disease develops into the intermediate link of hepatic sclerosis process and key can during this
The therapic opportunity leaned on.Because virus is the main reason for causing liver to be damaged repeatedly, to treat chronic liver disease in world wide at present
Two big strategies are i.e. antiviral and prevent liver fibrosis.Although antiviral therapy has remarkable progress in recent years, can not prevent
Liver fibrosis progression.Therefore, how another emphasis of liver disease as prevents liver fibrosis from excessively arriving hepatic sclerosis, thereupon
Be exploration to liver fibrosis mechanism.Studies have shown that liver fibrosis has invertibity, but hepatic sclerosis is irreversible, and its
Weak curative effect, therefore the drug for studying anti-hepatic fibrosis is most important.Anti-hepatic fibrosis medicines are mainly for treatment protopathy, guarantor at present
Protect liver cell, targeting influence Hepatic Stellate Cell Activation proliferation and apoptosis, inhibit collage synthesis and promote its degradation and regulation and control fine
Dimensionization relevant cell factor etc..Although having now been found that the drug of some anti-fibrosis, most curative effect is not sufficiently stable, and poison is secondary to be made
With larger or expensive, it is made clinically to be difficult to promote the use.Therefore, explore that a kind of curative effect is good, adverse reaction is few and
The low drug of expense is current anti-hepatic fibrosis urgent need.
Liver fibrosis is mainly caused by liver extracellular matrix (ECM) excessively deposition, and the hepatic stellate cells activated
(HSC) be ECM main source, be vital cell during liver fibrosis is formed.HSC is largely proliferated after being activated, a side
Face synthesizes and secretion ECM increases, and another aspect TIMPs synthesis increases, and reduces MMPs to ECM degradations so that ECM is synthesized
More than degradation, it is eventually developed to as liver fibrosis.In addition to this, the HSC of activation can also be by secreting TGF-β, TNF-α, IL-6
Static HSCs more etc. the activation of a variety of inflammatory factors, so that it is largely proliferated, inhibit itself apoptosis, and participating in portal hypertension
The various aspects such as formation play a role.It can be seen that the HSC of activation plays a crucial role in liver fibrosis is formed, inhibit HSC
Activation and proliferation, to induce its apoptosis be one of fundamental way of anti-hepatic fibrosis.The study found that the reverse and activation of liver fibrosis
HSC apoptosis it is closely related, promote activation HSC apoptosis can improve liver fibrosis to a certain extent.Therefore, pass through medicine at present
Object intervention induction HSC apoptosis is a Critical policies of anti-hepatic fibrosis.
Diallyl disulfide (Diallyl disulfide, DADS) is main liposoluble constituent in garlic, it is in garlic
Content is up to 60% in extract, and garlic is China's conventional foodstuff, have the advantages that be easy cultivation, it is cheap, derive from a wealth of sources.
DADS has multiple pharmacological effect, including the functions such as resisting pathogenic microbes, antitumor, anti-oxidant, anti-hepatotoxicity wind agitation.
It is had proven in the antitumor researchs of DADS can inhibit the increasing of the kinds of tumor cells such as gastric cancer, colorectal cancer, nasopharyngeal carcinoma
It grows and inducing apoptosis of tumour cell.Bcl-2 families are the relevant important member of Apoptosis, wherein anti-apoptosis factor bcl-2
And the balance promoted between two kinds of opposition albumen of antiapoptotic factors bax is the key that decision cell living or death, therefore, exploration is a kind of can targeting work
Drug with bcl-2 and bax is the important point of penetration of inducing cell apoptosis.Many researchs find that DADS can be by regulating and controlling bcl-2
Expression with bax accelerates apoptosis of tumor cells, and after the DADS processing stomach cancer cell 48 hours of 50-400umol/L, cell withers
It dies rate in concentration dependent to increase, be lowered in protein level bcl-2 expression, and bax is obviously raised, and prompts DADS may be under
Adjust bcl-2, up-regulation bax that the mitochondrial pathways is mediated to induce apoptosis in gastric cancer；In the research to esophageal squamous cell carcinoma apoptosis
Middle discovery weakens with the increase of DADS activities in mRNA level in-site bcl-2 expression, and bax expression enhancings, bcl-2/bax
Ratio obviously lower, prompt DADS that may promote cancer cell-apoptosis by reducing the ratio of bcl-2/bax.And in liver fiber
When change, bcl-2/bax ratios obviously rise in the HSC cells of activation, can improve liver after silence bcl-2 genes and high expression bax
Fibrosis, thus DADS can targeting in bcl-2 and bax promote activate HSC apoptosis to play anti-fibrosis effect.
Myricetin (Myricetin, 3,5,7- trihydroxy -2- (3,4,5- trihydroxy phenyl) -4H-1- benzofurans -4-
Ketone) it is yellow needles, molecular formula C15H10O8, relative molecular mass 318,324.0-325.5 DEG C of fusing point, ultraviolet spectra exists
There are absorption maximum, infrared spectrum to be shown with hydroxyl (3575,3380,3255cm at 376.5nm, 254nm-1), conjugation carbonyl
(1646cm-1), double bond and aromatic ring carbon skeleton vibration (1662,1550,1505,1454cm-1) absorb.The compound is dissolved in first
Alcohol, ethyl alcohol and acetone are slightly soluble in ethyl acetate, not soluble in water, petroleum ether (60-90 DEG C), chloroform, toluene and n-hexane, and resist
Photodissociation energy force difference is relatively stablized in acid condition, and is easily destroyed in partial neutral and alkaline environment.Myricetin is a kind of natural
Plant extracts is widely present in the fruits and vegetables such as onion, strawberry, and the content in red wine accounts for flavonoids total content 20%-50%,
Also known as myricetin, myricetin.Red bayberry is China's local product resource, rigid to the research of red bayberry in the world at present in view of regional disparity
Ground zero.
In recent years, certain progress has been obtained to the extraction separation of myricetin and purifying research.It is auxiliary using ionic liquid microwave
It helps abstraction technique to be extracted from myrica rubra leaf and isolates myricetin, compared with traditional heating or sour water solution, which can reduce significantly
Hydrolysis time simultaneously improves efficiency of pcr product.Using multiphase extraction technology, the MCM-41 synthesized as template using amino acid ion liquid
Mesopore molecular sieve extracts isolated myricetin as adsorbent from cupressaceae plant Japanese cypress, and recovery rate is reachable
0.018%, the method deviation is low, required quantity of solvent is few, the selectivity of separation and stability are high.In addition to this, vitaceae Portugal
The fruit of grape, Punicaceae plant pomegranate and the Myrsinacea plant coloring Japanese ardisia, the leaf and stem of crucifer radish also all may be used
To extract isolated myricetin.
Myricetin has anti-oxidant, anti-inflammatory, antitumor, anti-aging, hypoglycemic, lipid-loweringing, calmness, inhibits aberrant angiogenesis, protects
The multiple biological activities such as shield heart blood vessel.Recent studies have indicated that myricetin can be by improving insulin sensitivity, improving glycogen generation
Thank, para-insulin effect etc. reduce blood glucose effect.There is experiment to confirm that myricetin can be by improving insulin sensitivity, to change
Kind insulin resistance reduces blood glucose.There is researcher to establish Rat model of insulin-resistant by feeding the feed containing high sugar, passes through
After myricetin is handled 14 days, blood glucose, Triglycerides in Serum content and the insulin resistant power of rat are all substantially reduced.Pass through mouth
It takes the experiment of glucose sugar tolerance and finds that rat body insulin sensitivity index significantly improves, and shows that myricetin can increase rat pancreatic
Island element susceptibility.The experimental results showed that after myricetin effect human liver cancer cell HepG2, mitochondrial membrane potential can be destroyed, is promoted thin
Cytochrome C is discharged into cytoplasm, by the caspase-3 proteolysis of acute activation, simultaneous PARP protein degradations.Separately
Outside, myricetin can promote apoptotic protein Bax to be transferred on mitochondria, make the anti-expression reduction adjusted and die protein Bcl-2, mitochondria
The expression of pro-apoptotic protein B ad increases.In addition, myricetin promotes natural death of cerebral cells by Akt/p70s6kl signals, p70s6kl's
Phosphorylation, which occurs, for Serl63 can lower Bad albumen, show that myricetin can be logical by mitochondria pathway and Akt/p70s6kl/Bad
The tune of road induction HepG2 cells is died.In cancer of pancreas, cervical carcinoma and lung cancer cell line, myricetin is lured as the inhibitor of PI3K
Tune is led to die to reduce cell growth rate.
Currently, there is not been reported for the application for diallyl disulfide being combined with myricetin for preventing liver fibrosis.
Invention content
Liver fibrosis can be effectively prevented technical problem to be solved by the invention is to provide a kind of, is had no toxic side effect and drug resistance
Property, the natural pharmaceutical composition in active constituent source.
The present invention solves the above problems the technical scheme adopted is that providing a kind of pharmaceutical composition for treating liver fibrosis
Object, the wherein weight ratio of active constituent diallyl disulfide and myricetin are (1:1)~(1:9).
Preferably, in described pharmaceutical composition, the weight ratio of diallyl disulfide and myricetin is (1:3)~(1:9).
It is furthermore preferred that the weight ratio of diallyl disulfide and myricetin is 1:4.
Preferably, described pharmaceutical composition further comprises pharmaceutically acceptable auxiliary material.
It is furthermore preferred that the pharmaceutically acceptable auxiliary material is selected from starch, microcrystalline cellulose, sodium carboxymethylcellulose, gathers
It is one or more in vinylpyrrolidone, magnesium stearate and superfine silica gel powder.
Preferably, the dosage form of described pharmaceutical composition is tablet, capsule, injection powder needle, dripping pill etc., more preferably piece
Agent.
Preferably, in the pharmaceutical composition of 100 parts by weight, the diallyl disulfide containing 1-10 parts by weight and red bayberry
Element.
The present invention also provides a kind of application of aforementioned pharmaceutical compositions in the drug for preparing treatment liver fibrosis.
The invention has the advantages that：
It is surprising that by repeated tests, present inventors have unexpectedly found that by diallyl disulfide and myricetin group
Close has the effect of synergy using for the prevention of liver fibrosis, and cooperation other active components using effect is more preferably.
The two kinds of active components diallyl disulfide and myricetin of the present invention can generate while playing respective effect
Synergistic function significantly treats liver fibrosis.Diallyl disulfide and myricetin source are natural, safe and non-toxic, without side-effects.
Specific implementation mode
The present invention is further described with reference to embodiment, embodiments of the present invention are not limited thereto.Under
It states experimental method used in embodiment unless otherwise specified, is conventional method.
Embodiment 1 is prepared containing diallyl disulfide and myricetin (1:1) tablet
Take 5 parts by weight diallyl disulfides, the crystallite of the myricetin of 5 parts by weight, the starch of 50 parts by weight, 20 parts by weight fine
Dimension element, the polyvinylpyrrolidone of the sodium carboxymethylcellulose of 10 parts by weight and 9 parts by weight, wet granulation after mixing, after dry
Dry particl be added 0.5 parts by weight magnesium stearate and 0.5 parts by weight superfine silica gel powder, tabletting is made 100 parts by weight and contains two
Allyl disulfide and myricetin (weight ratio 1:1) tablet.
Embodiment 2 is prepared containing diallyl disulfide and myricetin (1:4) tablet
Take 2 parts by weight diallyl disulfides, the crystallite of the myricetin of 8 parts by weight, the starch of 50 parts by weight, 20 parts by weight fine
Dimension element, the polyvinylpyrrolidone of the sodium carboxymethylcellulose of 10 parts by weight and 9 parts by weight, wet granulation after mixing, after dry
Dry particl be added 0.5 parts by weight magnesium stearate and 0.5 parts by weight superfine silica gel powder, tabletting is made 100 parts by weight and contains two
Allyl disulfide and myricetin (weight ratio 1:4) tablet.
Embodiment 3 is prepared containing diallyl disulfide and myricetin (1:9) tablet
Take 1 parts by weight diallyl disulfide, the crystallite of the myricetin of 9 parts by weight, the starch of 50 parts by weight, 20 parts by weight fine
Dimension element, the polyvinylpyrrolidone of the sodium carboxymethylcellulose of 10 parts by weight and 9 parts by weight, wet granulation after mixing, after dry
Dry particl be added 0.5 parts by weight magnesium stearate and 0.5 parts by weight superfine silica gel powder, tabletting is made 100 parts by weight and contains two
Allyl disulfide and myricetin (weight ratio 1:9) tablet.
Test example 1, mtt assay detect the present composition to HSC-T6The influence of proliferation
(1) test material
Cultured rat hepatic stellate cells cell strain (HSC-T6) culture：Use volume fraction for 6% calf serum and 1 ×
105The DMEM culture solutions of the penicillin of IU/L, the streptomysin of 100mg/L, in 37 DEG C, 5%CO2It is being incubated under conditions of saturated humidity
It educates in case and cultivates, often cross 2-3d and carry out changing liquid.
(2) experiment grouping
1. control group：The calf serum and 1 × 10 that volume fraction is 6%5The penicillin of IU/L, the streptomysin of 100mg/L
DMEM culture mediums.
2. diallyl disulfide group：It is added in the culture medium of control group through the diluted diallyl disulfides of DMSO, is prepared
At the culture medium of diallyl disulfide final concentration of 25 μ g/ml and 50 μ g/ml, diallyl disulfide group is obtained.
3. myricetin group：It is added through the diluted myricetins of DMSO in the culture medium of control group, it is dense eventually to be configured to myricetin
Degree is the culture medium of 25 μ g/ml and 50 μ g/ml, obtains myricetin group.
4. pharmaceutical composition group：Following medicinal mixtures are added in the culture medium of control group, obtain each medicinal mixture group.
Mixture group 1 is that weight ratio is 1:1 diallyl disulfide and the pharmaceutical composition of myricetin, after DMSO dilutes
It is added in culture medium, is configured to the culture medium of the final concentration of 25 μ g/ml and 50 μ g/ml of hybrid medicine respectively；
Mixture group 2 is that weight ratio is 1:4 diallyl disulfide and the pharmaceutical composition of myricetin, after DMSO dilutes
It is added in culture medium, is configured to the culture medium of the final concentration of 25 μ g/ml and 50 μ g/ml of hybrid medicine respectively；
Mixture group 3 is that weight ratio is 1:9 diallyl disulfide and the pharmaceutical composition of myricetin, after DMSO dilutes
It is added in culture medium, is configured to the culture medium of the final concentration of 25 μ g/ml and 50 μ g/ml of hybrid medicine respectively.
(3) process is tested
The HSC-T of logarithmic growth phase6Cell is made 5 × 105The cell suspension of/ml, in 96 well culture plates, every 1
100 μ l cell suspensions are all added in hole, then are separately added into the culture medium of the control group and each drug test group of 100 μ l, and each group real
It tests and is repeated 3 times.Then 5%CO is put into2Cultivated in the incubator of saturated humidity, temperature is 37 DEG C, the time be for 24 hours and 48h,
It puts 20 μ l MTT (5mg/m1) solution into each hole to be further incubated for, time 4h, supernatant discards.Finally every 1
It is put into 100 μ l DMSO in a hole, is placed on oscillator, carries out the oscillation of 10min, the crystal in solution is made to obtain adequately
Dissolving.Using enzyme-labeled immunity analyzer, the OD values per hole are detected, wavelength when measurement is 570nm.Then to the average suppression of drug
Rate processed is calculated.
The average inhibition (%) of drug：Fa=(1- test groups OD values/control group OD values) × 100%.
(4) test result
Each test group (a concentration of 25 μ g/ml and 50 μ g/ml) is for 24 hours with 48h to HSC-T6The inhibiting effect of cell such as table 1
It is shown.
1 pharmaceutical composition of the present invention of table is to HSC-T6The influence of proliferation
As can be seen from Table 1, under the conditions of 25 μ g/ml and 50 μ g/ml, diallyl disulfide and myricetin are to HSC-T6Cell
Proliferation have different degrees of inhibiting effect, and show that action time is longer with the inhibition data of 48h for 24 hours, inhibition is got over
Obviously.In addition, under the premise of active constituents of medicine total amount is identical, the mixture of the two is to HSC-T6The inhibition of cell Proliferation is made
Two kinds of drugs are used alone with being substantially better than, show the pharmaceutical composition of the present invention for preventing liver fibrosis that there is synergy
Effect.Wherein diallyl disulfide and myricetin weight ratio are 1:The inhibiting effect of 4 mixture group 2 is most strong, produces difficulty
With expected good therapeutic effect.
Claims (9)
1. a kind of anti-hepatic fibrosis medicines composition containing diallyl disulfide, which is characterized in that wherein two allyl of active constituent
The weight ratio of two sulphur of base and myricetin is (1:1)~(1:9).
2. pharmaceutical composition according to claim 1, which is characterized in that the weight ratio of diallyl disulfide and myricetin is
(1:3)~(1:9).
3. pharmaceutical composition according to claim 2, which is characterized in that the weight ratio of diallyl disulfide and myricetin is
1:4。
4. pharmaceutical composition according to claim 1, which is characterized in that described pharmaceutical composition further comprises pharmacy
Upper acceptable auxiliary material.
5. pharmaceutical composition according to claim 4, which is characterized in that the pharmaceutically acceptable auxiliary material, which is selected from, to form sediment
It is one or more in powder, microcrystalline cellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone, magnesium stearate and superfine silica gel powder.
6. pharmaceutical composition according to claim 1, which is characterized in that the dosage form of described pharmaceutical composition is tablet, glue
Wafer, injection powder needle, dripping pill.
7. pharmaceutical composition according to claim 6, which is characterized in that the dosage form of described pharmaceutical composition is tablet.
8. pharmaceutical composition according to claim 1, which is characterized in that in the pharmaceutical composition of 100 parts by weight, contain
The diallyl disulfide and myricetin of 1-10 parts by weight.
9. application of the claim 1-8 any one of them pharmaceutical composition in the drug for preparing treatment liver fibrosis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710872532.8A CN107536830B (en) | 2017-09-25 | 2017-09-25 | Anti-hepatic fibrosis medicines composition containing diallyl disulfide |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710872532.8A CN107536830B (en) | 2017-09-25 | 2017-09-25 | Anti-hepatic fibrosis medicines composition containing diallyl disulfide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107536830A CN107536830A (en) | 2018-01-05 |
| CN107536830B true CN107536830B (en) | 2018-10-02 |
Family
ID=60964643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710872532.8A Active CN107536830B (en) | 2017-09-25 | 2017-09-25 | Anti-hepatic fibrosis medicines composition containing diallyl disulfide |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107536830B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220062223A1 (en) * | 2018-11-14 | 2022-03-03 | The Trustees Of Princeton University | Dihydromyricetin spray-dried dispension formulations and methods for forming them |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101040995A (en) * | 2006-03-20 | 2007-09-26 | 沈联慈 | Valid target of garlic oil and the application in preparing many kinds of medicine |
| CN101254186A (en) * | 2008-04-03 | 2008-09-03 | 沈阳药科大学 | Medicament use of myricetin |
-
2017
- 2017-09-25 CN CN201710872532.8A patent/CN107536830B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN107536830A (en) | 2018-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009514960A (en) | Herbal extract powder and its preparation and use | |
| WO2023065376A1 (en) | Use of composition comprising astilbin and/or isomer thereof in preparation of drug for treating psoriasis | |
| CN106798762A (en) | One Plant Extracts and its preparation method and application | |
| CN107536830B (en) | Anti-hepatic fibrosis medicines composition containing diallyl disulfide | |
| CN106188209B (en) | A kind of melbine conjugate for having antitumor and activity of resisting tumor metastasis concurrently and its application | |
| CN105963304B (en) | A kind of pharmaceutical composition and its application in preparation of anti-tumor drugs of melbine and ursolic acid and its derivative | |
| CN105399794B (en) | Fructus momordicae triterpene saponin and salt thereof, preparation method and applications of fructus momordicae triterpene saponin and salt thereof, and pharmaceutical composition containing fructus momordicae triterpene saponin and salt thereof | |
| CN1919339B (en) | Cucurbitacin nano preparation comprising protein, preparation method and use thereof | |
| US9629385B2 (en) | Dietary composition containing cistanche deserticola polysaccharide with inhibitory effects on colon cancer | |
| TW201109011A (en) | Cyclohexenone chemical compounds of Antrodia cinnamomea for suppressing the growth of gastric cancer tumor cell | |
| CN103655559B (en) | Horned artemisia ester alkali compounds is preparing the application in anti-breast cancer medicines | |
| CN103239488A (en) | Application of crude extract product of Ardisia mamillata Hance | |
| Anyu et al. | Cultivated cordyceps: a tale of two treasured mushrooms | |
| KR101529279B1 (en) | Liver cytoprotective composition comprising an extract of brassica juncea coss. and compounds isolated therefrom | |
| KR20140120756A (en) | Anti-inflammatory pharmaceutical composition comprising tangerine pericarp and Psidium guajava extract | |
| WO2016169489A1 (en) | Application of forsythin, forsythin derivative, composition of forsythin and forsythin lignans in preparing medicine or health care product for preventing or/and treating liver injury | |
| CN103204860B (en) | There is the amaryllidaceae alkaloid compounds of neuroprotective | |
| KR20210058760A (en) | Composition for preventing or treating renal disease comprising Zizyphus jujuba MILL extract | |
| TW202017578A (en) | Preparation method and pharmaceutical composition for the extarct and composition of antrodia cinnamomea. | |
| KR100485936B1 (en) | Anticarcinogenic constituents of ginsenoside Rh2 and Rg3 | |
| CN104546867A (en) | Application of ilicin A to preparation of lipid-regulating drug preparation | |
| CN105267619B (en) | The anti-tumor Chinese medicine compound extract that a kind of suppression ras proto-oncogenes are overexpressed | |
| CN103054848B (en) | Pharmaceutical composition for preventing or treating cardiovascnlar and cerebrovascular diseases | |
| CN103193788B (en) | Lycorine alkaline compound with neuroprotective effect | |
| TWI448295B (en) | The anti-human urothelial carcinoma of supercritical carbon dioxide extract of cinnamomum subavenium, and the preparation process and uses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190626 Address after: 310020 Room 1503-1, Xizi International Center, Jianggan District, Hangzhou City, Zhejiang Province Patentee after: Hangzhou Baiti Biotechnology Co.,Ltd. Address before: Room 2 1503-3, Xizi International Center, Jianggan District, Hangzhou City, Zhejiang Province, 310000 Patentee before: HANGZHOU POOLINGMED BIOTECHNOLOGY CO.,LTD. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230328 Address after: 100000 No. 708, Floor 7, No. 157, Dongsi South Street, Dongcheng District, Beijing Patentee after: Beijing Baiti Biotechnology Co.,Ltd. Address before: 310020 Room 1503-1, Xizi International Center, Jianggan District, Hangzhou City, Zhejiang Province Patentee before: Hangzhou Baiti Biotechnology Co.,Ltd. |